Clinical Trial

Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN

Study acronym: REWRITe
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 7, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study evaluate the regional (neck) nodal control of durvalumab in combination with RT restricted to the primary tumor and the immediately adjacent nodal level (i.e. without prophylactic neck irradiation) in N0 patients with SCCHN.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2018-10-30; most recent amendment 2025-05-06.
Status change: Recruiting → Active, Not Recruiting 2022-11-22
Status change: Not Yet Recruiting → Recruiting 2019-09-05
Trial Details
NCT Number NCT03726775
Lead Sponsor Groupe Oncologie Radiotherapie Tete et Cou
Collaborators: UNICANCER, Center Eugene Marquis
Conditions HNSCC
Enrollment 61 participants
Start Date 2019-07-17
Primary Completion 2026-07 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-05-07